nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—HTR2B—Sorafenib—kidney cancer	0.179	0.292	CbGbCtD
Agomelatine—HTR2C—Sorafenib—kidney cancer	0.117	0.19	CbGbCtD
Agomelatine—CYP1A2—Pazopanib—kidney cancer	0.0731	0.119	CbGbCtD
Agomelatine—CYP2C9—Capecitabine—kidney cancer	0.0687	0.112	CbGbCtD
Agomelatine—CYP1A2—Erlotinib—kidney cancer	0.0522	0.0851	CbGbCtD
Agomelatine—CYP2C9—Paclitaxel—kidney cancer	0.043	0.0702	CbGbCtD
Agomelatine—CYP1A2—Sorafenib—kidney cancer	0.0424	0.0692	CbGbCtD
Agomelatine—CYP2C9—Sorafenib—kidney cancer	0.0382	0.0623	CbGbCtD
Agomelatine—Nabumetone—PTGS1—kidney cancer	0.00232	0.291	CrCbGaD
Agomelatine—Nabumetone—PTGS2—kidney cancer	0.00133	0.166	CrCbGaD
Agomelatine—Naproxen—PTGS1—kidney cancer	0.00108	0.135	CrCbGaD
Agomelatine—Indomethacin—PTGS1—kidney cancer	0.000871	0.109	CrCbGaD
Agomelatine—Melatonin—CYP1A1—kidney cancer	0.000847	0.106	CrCbGaD
Agomelatine—Insomnia—Erlotinib—kidney cancer	0.000707	0.00214	CcSEcCtD
Agomelatine—Mental disorder—Vincristine—kidney cancer	0.000706	0.00214	CcSEcCtD
Agomelatine—Diarrhoea—Pazopanib—kidney cancer	0.000702	0.00213	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000701	0.00213	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Everolimus—kidney cancer	0.0007	0.00212	CcSEcCtD
Agomelatine—Infection—Sorafenib—kidney cancer	0.000699	0.00212	CcSEcCtD
Agomelatine—Fatigue—Everolimus—kidney cancer	0.000699	0.00212	CcSEcCtD
Agomelatine—Constipation—Vinblastine—kidney cancer	0.000696	0.00211	CcSEcCtD
Agomelatine—Constipation—Everolimus—kidney cancer	0.000693	0.0021	CcSEcCtD
Agomelatine—Vomiting—Temsirolimus—kidney cancer	0.000693	0.0021	CcSEcCtD
Agomelatine—Dry mouth—Sunitinib—kidney cancer	0.000691	0.00209	CcSEcCtD
Agomelatine—Nervous system disorder—Sorafenib—kidney cancer	0.00069	0.00209	CcSEcCtD
Agomelatine—Dyspepsia—Erlotinib—kidney cancer	0.000688	0.00209	CcSEcCtD
Agomelatine—Skin disorder—Sorafenib—kidney cancer	0.000683	0.00207	CcSEcCtD
Agomelatine—Headache—Temsirolimus—kidney cancer	0.000683	0.00207	CcSEcCtD
Agomelatine—Nasopharyngitis—Capecitabine—kidney cancer	0.000679	0.00206	CcSEcCtD
Agomelatine—Dizziness—Pazopanib—kidney cancer	0.000679	0.00206	CcSEcCtD
Agomelatine—Back pain—Vincristine—kidney cancer	0.000679	0.00206	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000675	0.00205	CcSEcCtD
Agomelatine—Hepatobiliary disease—Paclitaxel—kidney cancer	0.000674	0.00204	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Doxorubicin—kidney cancer	0.000674	0.00204	CcSEcCtD
Agomelatine—Fatigue—Erlotinib—kidney cancer	0.000674	0.00204	CcSEcCtD
Agomelatine—Infection—Sunitinib—kidney cancer	0.000673	0.00204	CcSEcCtD
Agomelatine—Constipation—Erlotinib—kidney cancer	0.000669	0.00203	CcSEcCtD
Agomelatine—Abnormal dreams—Doxorubicin—kidney cancer	0.000666	0.00202	CcSEcCtD
Agomelatine—Gastrointestinal pain—Vinblastine—kidney cancer	0.000665	0.00202	CcSEcCtD
Agomelatine—Nervous system disorder—Sunitinib—kidney cancer	0.000664	0.00201	CcSEcCtD
Agomelatine—Gastrointestinal pain—Everolimus—kidney cancer	0.000663	0.00201	CcSEcCtD
Agomelatine—Skin disorder—Sunitinib—kidney cancer	0.000658	0.00199	CcSEcCtD
Agomelatine—Influenza—Capecitabine—kidney cancer	0.000656	0.00199	CcSEcCtD
Agomelatine—Vomiting—Pazopanib—kidney cancer	0.000653	0.00198	CcSEcCtD
Agomelatine—Nausea—Temsirolimus—kidney cancer	0.000647	0.00196	CcSEcCtD
Agomelatine—Agitation—Vincristine—kidney cancer	0.000645	0.00196	CcSEcCtD
Agomelatine—Back pain—Gemcitabine—kidney cancer	0.000644	0.00195	CcSEcCtD
Agomelatine—Abdominal pain—Vinblastine—kidney cancer	0.000643	0.00195	CcSEcCtD
Agomelatine—Headache—Pazopanib—kidney cancer	0.000643	0.00195	CcSEcCtD
Agomelatine—Abdominal pain—Everolimus—kidney cancer	0.000641	0.00194	CcSEcCtD
Agomelatine—Gastrointestinal pain—Erlotinib—kidney cancer	0.000639	0.00194	CcSEcCtD
Agomelatine—Infection—Dactinomycin—kidney cancer	0.000637	0.00193	CcSEcCtD
Agomelatine—Vertigo—Vincristine—kidney cancer	0.00063	0.00191	CcSEcCtD
Agomelatine—Connective tissue disorder—Paclitaxel—kidney cancer	0.000629	0.00191	CcSEcCtD
Agomelatine—Dyspepsia—Sorafenib—kidney cancer	0.000619	0.00188	CcSEcCtD
Agomelatine—Abdominal pain—Erlotinib—kidney cancer	0.000618	0.00187	CcSEcCtD
Agomelatine—Naproxen—PTGS2—kidney cancer	0.000615	0.077	CrCbGaD
Agomelatine—Insomnia—Sunitinib—kidney cancer	0.000612	0.00186	CcSEcCtD
Agomelatine—Nausea—Pazopanib—kidney cancer	0.00061	0.00185	CcSEcCtD
Agomelatine—Paraesthesia—Sunitinib—kidney cancer	0.000608	0.00184	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000607	0.00184	CcSEcCtD
Agomelatine—Fatigue—Sorafenib—kidney cancer	0.000607	0.00184	CcSEcCtD
Agomelatine—Constipation—Sorafenib—kidney cancer	0.000602	0.00182	CcSEcCtD
Agomelatine—Eye disorder—Paclitaxel—kidney cancer	0.000598	0.00181	CcSEcCtD
Agomelatine—Weight increased—Capecitabine—kidney cancer	0.000597	0.00181	CcSEcCtD
Agomelatine—Tinnitus—Paclitaxel—kidney cancer	0.000597	0.00181	CcSEcCtD
Agomelatine—Dyspepsia—Sunitinib—kidney cancer	0.000596	0.00181	CcSEcCtD
Agomelatine—Weight decreased—Capecitabine—kidney cancer	0.000594	0.0018	CcSEcCtD
Agomelatine—Infestation—Capecitabine—kidney cancer	0.000585	0.00177	CcSEcCtD
Agomelatine—Infestation NOS—Capecitabine—kidney cancer	0.000585	0.00177	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000584	0.00177	CcSEcCtD
Agomelatine—Asthenia—Vinblastine—kidney cancer	0.000584	0.00177	CcSEcCtD
Agomelatine—Fatigue—Sunitinib—kidney cancer	0.000584	0.00177	CcSEcCtD
Agomelatine—Depression—Capecitabine—kidney cancer	0.000584	0.00177	CcSEcCtD
Agomelatine—Asthenia—Everolimus—kidney cancer	0.000582	0.00176	CcSEcCtD
Agomelatine—Constipation—Sunitinib—kidney cancer	0.000579	0.00176	CcSEcCtD
Agomelatine—Gastrointestinal pain—Sorafenib—kidney cancer	0.000575	0.00174	CcSEcCtD
Agomelatine—Pruritus—Everolimus—kidney cancer	0.000573	0.00174	CcSEcCtD
Agomelatine—Jaundice—Capecitabine—kidney cancer	0.00057	0.00173	CcSEcCtD
Agomelatine—Infection—Vincristine—kidney cancer	0.000569	0.00172	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—kidney cancer	0.000563	0.00171	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000563	0.00171	CcSEcCtD
Agomelatine—Nervous system disorder—Vincristine—kidney cancer	0.000562	0.0017	CcSEcCtD
Agomelatine—Asthenia—Erlotinib—kidney cancer	0.000561	0.0017	CcSEcCtD
Agomelatine—Mental disorder—Paclitaxel—kidney cancer	0.000561	0.0017	CcSEcCtD
Agomelatine—Urticaria—Sorafenib—kidney cancer	0.000559	0.00169	CcSEcCtD
Agomelatine—Diarrhoea—Vinblastine—kidney cancer	0.000557	0.00169	CcSEcCtD
Agomelatine—Abdominal pain—Sorafenib—kidney cancer	0.000556	0.00169	CcSEcCtD
Agomelatine—Diarrhoea—Everolimus—kidney cancer	0.000555	0.00168	CcSEcCtD
Agomelatine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000554	0.00168	CcSEcCtD
Agomelatine—Hyperhidrosis—Vincristine—kidney cancer	0.000554	0.00168	CcSEcCtD
Agomelatine—Hepatobiliary disease—Capecitabine—kidney cancer	0.000553	0.00168	CcSEcCtD
Agomelatine—Pruritus—Erlotinib—kidney cancer	0.000553	0.00168	CcSEcCtD
Agomelatine—Fatigue—Dactinomycin—kidney cancer	0.000553	0.00168	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—kidney cancer	0.000545	0.00165	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—kidney cancer	0.000545	0.00165	CcSEcCtD
Agomelatine—Infection—Gemcitabine—kidney cancer	0.00054	0.00164	CcSEcCtD
Agomelatine—Back pain—Paclitaxel—kidney cancer	0.000539	0.00163	CcSEcCtD
Agomelatine—Dizziness—Vinblastine—kidney cancer	0.000538	0.00163	CcSEcCtD
Agomelatine—Dizziness—Everolimus—kidney cancer	0.000536	0.00163	CcSEcCtD
Agomelatine—Abdominal pain—Sunitinib—kidney cancer	0.000535	0.00162	CcSEcCtD
Agomelatine—Diarrhoea—Erlotinib—kidney cancer	0.000535	0.00162	CcSEcCtD
Agomelatine—Nervous system disorder—Gemcitabine—kidney cancer	0.000533	0.00162	CcSEcCtD
Agomelatine—Skin disorder—Gemcitabine—kidney cancer	0.000528	0.0016	CcSEcCtD
Agomelatine—Hepatitis—Capecitabine—kidney cancer	0.000525	0.00159	CcSEcCtD
Agomelatine—Vision blurred—Paclitaxel—kidney cancer	0.000525	0.00159	CcSEcCtD
Agomelatine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000525	0.00159	CcSEcCtD
Agomelatine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000524	0.00159	CcSEcCtD
Agomelatine—Tremor—Paclitaxel—kidney cancer	0.000522	0.00158	CcSEcCtD
Agomelatine—Insomnia—Vincristine—kidney cancer	0.000518	0.00157	CcSEcCtD
Agomelatine—Vomiting—Vinblastine—kidney cancer	0.000517	0.00157	CcSEcCtD
Agomelatine—Dizziness—Erlotinib—kidney cancer	0.000517	0.00157	CcSEcCtD
Agomelatine—Connective tissue disorder—Capecitabine—kidney cancer	0.000516	0.00157	CcSEcCtD
Agomelatine—Vomiting—Everolimus—kidney cancer	0.000515	0.00156	CcSEcCtD
Agomelatine—Paraesthesia—Vincristine—kidney cancer	0.000514	0.00156	CcSEcCtD
Agomelatine—Agitation—Paclitaxel—kidney cancer	0.000512	0.00155	CcSEcCtD
Agomelatine—Headache—Vinblastine—kidney cancer	0.00051	0.00155	CcSEcCtD
Agomelatine—Angioedema—Paclitaxel—kidney cancer	0.000509	0.00154	CcSEcCtD
Agomelatine—Headache—Everolimus—kidney cancer	0.000508	0.00154	CcSEcCtD
Agomelatine—Abdominal pain—Dactinomycin—kidney cancer	0.000507	0.00154	CcSEcCtD
Agomelatine—Asthenia—Sorafenib—kidney cancer	0.000505	0.00153	CcSEcCtD
Agomelatine—Vertigo—Paclitaxel—kidney cancer	0.000501	0.00152	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—kidney cancer	0.000498	0.0624	CrCbGaD
Agomelatine—Pruritus—Sorafenib—kidney cancer	0.000498	0.00151	CcSEcCtD
Agomelatine—Vomiting—Erlotinib—kidney cancer	0.000497	0.00151	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000494	0.0015	CcSEcCtD
Agomelatine—Fatigue—Vincristine—kidney cancer	0.000494	0.0015	CcSEcCtD
Agomelatine—Insomnia—Gemcitabine—kidney cancer	0.000491	0.00149	CcSEcCtD
Agomelatine—Eye disorder—Capecitabine—kidney cancer	0.000491	0.00149	CcSEcCtD
Agomelatine—Headache—Erlotinib—kidney cancer	0.00049	0.00149	CcSEcCtD
Agomelatine—Tinnitus—Capecitabine—kidney cancer	0.00049	0.00149	CcSEcCtD
Agomelatine—Constipation—Vincristine—kidney cancer	0.00049	0.00148	CcSEcCtD
Agomelatine—Paraesthesia—Gemcitabine—kidney cancer	0.000488	0.00148	CcSEcCtD
Agomelatine—Asthenia—Sunitinib—kidney cancer	0.000486	0.00147	CcSEcCtD
Agomelatine—Nausea—Vinblastine—kidney cancer	0.000483	0.00147	CcSEcCtD
Agomelatine—Somnolence—Gemcitabine—kidney cancer	0.000483	0.00146	CcSEcCtD
Agomelatine—Migraine—Doxorubicin—kidney cancer	0.000482	0.00146	CcSEcCtD
Agomelatine—Nausea—Everolimus—kidney cancer	0.000481	0.00146	CcSEcCtD
Agomelatine—Diarrhoea—Sorafenib—kidney cancer	0.000481	0.00146	CcSEcCtD
Agomelatine—Pruritus—Sunitinib—kidney cancer	0.000479	0.00145	CcSEcCtD
Agomelatine—Anxiety—Paclitaxel—kidney cancer	0.000473	0.00143	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—kidney cancer	0.000473	0.00143	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000471	0.00143	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000469	0.00142	CcSEcCtD
Agomelatine—Fatigue—Gemcitabine—kidney cancer	0.000468	0.00142	CcSEcCtD
Agomelatine—Gastrointestinal pain—Vincristine—kidney cancer	0.000468	0.00142	CcSEcCtD
Agomelatine—Dizziness—Sorafenib—kidney cancer	0.000465	0.00141	CcSEcCtD
Agomelatine—Constipation—Gemcitabine—kidney cancer	0.000465	0.00141	CcSEcCtD
Agomelatine—Nausea—Erlotinib—kidney cancer	0.000465	0.00141	CcSEcCtD
Agomelatine—Dry mouth—Paclitaxel—kidney cancer	0.000464	0.00141	CcSEcCtD
Agomelatine—Diarrhoea—Sunitinib—kidney cancer	0.000463	0.0014	CcSEcCtD
Agomelatine—Mental disorder—Capecitabine—kidney cancer	0.00046	0.0014	CcSEcCtD
Agomelatine—Asthenia—Dactinomycin—kidney cancer	0.00046	0.00139	CcSEcCtD
Agomelatine—Abdominal pain—Vincristine—kidney cancer	0.000453	0.00137	CcSEcCtD
Agomelatine—Infection—Paclitaxel—kidney cancer	0.000452	0.00137	CcSEcCtD
Agomelatine—Dizziness—Sunitinib—kidney cancer	0.000448	0.00136	CcSEcCtD
Agomelatine—Vomiting—Sorafenib—kidney cancer	0.000447	0.00136	CcSEcCtD
Agomelatine—Nervous system disorder—Paclitaxel—kidney cancer	0.000446	0.00135	CcSEcCtD
Agomelatine—Back pain—Capecitabine—kidney cancer	0.000442	0.00134	CcSEcCtD
Agomelatine—Skin disorder—Paclitaxel—kidney cancer	0.000442	0.00134	CcSEcCtD
Agomelatine—Headache—Sorafenib—kidney cancer	0.000441	0.00134	CcSEcCtD
Agomelatine—Hyperhidrosis—Paclitaxel—kidney cancer	0.00044	0.00133	CcSEcCtD
Agomelatine—Diarrhoea—Dactinomycin—kidney cancer	0.000439	0.00133	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—kidney cancer	0.000438	0.00133	CcSEcCtD
Agomelatine—Vision blurred—Capecitabine—kidney cancer	0.000431	0.00131	CcSEcCtD
Agomelatine—Vomiting—Sunitinib—kidney cancer	0.00043	0.00131	CcSEcCtD
Agomelatine—Tremor—Capecitabine—kidney cancer	0.000428	0.0013	CcSEcCtD
Agomelatine—Headache—Sunitinib—kidney cancer	0.000424	0.00129	CcSEcCtD
Agomelatine—Indomethacin—ABCB1—kidney cancer	0.000424	0.0531	CrCbGaD
Agomelatine—Influenza—Doxorubicin—kidney cancer	0.000423	0.00128	CcSEcCtD
Agomelatine—Nausea—Sorafenib—kidney cancer	0.000418	0.00127	CcSEcCtD
Agomelatine—Insomnia—Paclitaxel—kidney cancer	0.000411	0.00125	CcSEcCtD
Agomelatine—Vertigo—Capecitabine—kidney cancer	0.000411	0.00125	CcSEcCtD
Agomelatine—Asthenia—Vincristine—kidney cancer	0.000411	0.00125	CcSEcCtD
Agomelatine—Paraesthesia—Paclitaxel—kidney cancer	0.000408	0.00124	CcSEcCtD
Agomelatine—Vomiting—Dactinomycin—kidney cancer	0.000407	0.00124	CcSEcCtD
Agomelatine—Somnolence—Paclitaxel—kidney cancer	0.000404	0.00123	CcSEcCtD
Agomelatine—Nausea—Sunitinib—kidney cancer	0.000402	0.00122	CcSEcCtD
Agomelatine—Dyspepsia—Paclitaxel—kidney cancer	0.0004	0.00121	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000393	0.00119	CcSEcCtD
Agomelatine—Fatigue—Paclitaxel—kidney cancer	0.000392	0.00119	CcSEcCtD
Agomelatine—Diarrhoea—Vincristine—kidney cancer	0.000392	0.00119	CcSEcCtD
Agomelatine—Asthenia—Gemcitabine—kidney cancer	0.00039	0.00118	CcSEcCtD
Agomelatine—Constipation—Paclitaxel—kidney cancer	0.000389	0.00118	CcSEcCtD
Agomelatine—Anxiety—Capecitabine—kidney cancer	0.000388	0.00118	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000387	0.00117	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—kidney cancer	0.000385	0.00117	CcSEcCtD
Agomelatine—Pruritus—Gemcitabine—kidney cancer	0.000384	0.00117	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—kidney cancer	0.000383	0.00116	CcSEcCtD
Agomelatine—Dry mouth—Capecitabine—kidney cancer	0.000381	0.00115	CcSEcCtD
Agomelatine—Nausea—Dactinomycin—kidney cancer	0.000381	0.00115	CcSEcCtD
Agomelatine—Dizziness—Vincristine—kidney cancer	0.000379	0.00115	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—kidney cancer	0.000377	0.00114	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—kidney cancer	0.000377	0.00114	CcSEcCtD
Agomelatine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000372	0.00113	CcSEcCtD
Agomelatine—Diarrhoea—Gemcitabine—kidney cancer	0.000372	0.00113	CcSEcCtD
Agomelatine—Infection—Capecitabine—kidney cancer	0.000371	0.00112	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—kidney cancer	0.000368	0.00111	CcSEcCtD
Agomelatine—Nervous system disorder—Capecitabine—kidney cancer	0.000366	0.00111	CcSEcCtD
Agomelatine—Vomiting—Vincristine—kidney cancer	0.000364	0.0011	CcSEcCtD
Agomelatine—Skin disorder—Capecitabine—kidney cancer	0.000363	0.0011	CcSEcCtD
Agomelatine—Urticaria—Paclitaxel—kidney cancer	0.000361	0.0011	CcSEcCtD
Agomelatine—Hyperhidrosis—Capecitabine—kidney cancer	0.000361	0.00109	CcSEcCtD
Agomelatine—Abdominal pain—Paclitaxel—kidney cancer	0.00036	0.00109	CcSEcCtD
Agomelatine—Headache—Vincristine—kidney cancer	0.000359	0.00109	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000357	0.00108	CcSEcCtD
Agomelatine—Vomiting—Gemcitabine—kidney cancer	0.000345	0.00105	CcSEcCtD
Agomelatine—Headache—Gemcitabine—kidney cancer	0.00034	0.00103	CcSEcCtD
Agomelatine—Nausea—Vincristine—kidney cancer	0.00034	0.00103	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—kidney cancer	0.000339	0.00103	CcSEcCtD
Agomelatine—Insomnia—Capecitabine—kidney cancer	0.000338	0.00102	CcSEcCtD
Agomelatine—Paraesthesia—Capecitabine—kidney cancer	0.000335	0.00102	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—kidney cancer	0.000333	0.00101	CcSEcCtD
Agomelatine—Dyspepsia—Capecitabine—kidney cancer	0.000329	0.000996	CcSEcCtD
Agomelatine—Asthenia—Paclitaxel—kidney cancer	0.000326	0.000989	CcSEcCtD
Agomelatine—Nausea—Gemcitabine—kidney cancer	0.000323	0.000978	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000322	0.000977	CcSEcCtD
Agomelatine—Fatigue—Capecitabine—kidney cancer	0.000322	0.000976	CcSEcCtD
Agomelatine—Pruritus—Paclitaxel—kidney cancer	0.000322	0.000976	CcSEcCtD
Agomelatine—Constipation—Capecitabine—kidney cancer	0.000319	0.000968	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—kidney cancer	0.000316	0.00096	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—kidney cancer	0.000316	0.000957	CcSEcCtD
Agomelatine—Diarrhoea—Paclitaxel—kidney cancer	0.000311	0.000944	CcSEcCtD
Agomelatine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000305	0.000925	CcSEcCtD
Agomelatine—Dizziness—Paclitaxel—kidney cancer	0.000301	0.000912	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—kidney cancer	0.000297	0.0009	CcSEcCtD
Agomelatine—Urticaria—Capecitabine—kidney cancer	0.000296	0.000899	CcSEcCtD
Agomelatine—Abdominal pain—Capecitabine—kidney cancer	0.000295	0.000895	CcSEcCtD
Agomelatine—Vomiting—Paclitaxel—kidney cancer	0.000289	0.000877	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—kidney cancer	0.000285	0.000865	CcSEcCtD
Agomelatine—Headache—Paclitaxel—kidney cancer	0.000285	0.000864	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—kidney cancer	0.000278	0.000842	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—kidney cancer	0.000271	0.000821	CcSEcCtD
Agomelatine—Nausea—Paclitaxel—kidney cancer	0.00027	0.000819	CcSEcCtD
Agomelatine—Asthenia—Capecitabine—kidney cancer	0.000268	0.000812	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—kidney cancer	0.000265	0.000803	CcSEcCtD
Agomelatine—Pruritus—Capecitabine—kidney cancer	0.000264	0.000801	CcSEcCtD
Agomelatine—Diarrhoea—Capecitabine—kidney cancer	0.000255	0.000774	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—kidney cancer	0.00025	0.000758	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000249	0.000756	CcSEcCtD
Agomelatine—Dizziness—Capecitabine—kidney cancer	0.000247	0.000748	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—kidney cancer	0.000245	0.000744	CcSEcCtD
Agomelatine—Infection—Doxorubicin—kidney cancer	0.000239	0.000725	CcSEcCtD
Agomelatine—Vomiting—Capecitabine—kidney cancer	0.000237	0.00072	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—kidney cancer	0.000236	0.000715	CcSEcCtD
Agomelatine—Headache—Capecitabine—kidney cancer	0.000234	0.000709	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—kidney cancer	0.000234	0.000709	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—kidney cancer	0.000233	0.000705	CcSEcCtD
Agomelatine—Nausea—Capecitabine—kidney cancer	0.000222	0.000672	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—kidney cancer	0.000218	0.00066	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—kidney cancer	0.000216	0.000655	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—kidney cancer	0.000214	0.000649	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—kidney cancer	0.000212	0.000642	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000208	0.00063	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—kidney cancer	0.000207	0.000629	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—kidney cancer	0.000206	0.000624	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000197	0.000597	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—kidney cancer	0.000191	0.00058	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—kidney cancer	0.00019	0.000577	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—kidney cancer	0.000173	0.000523	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—kidney cancer	0.00017	0.000516	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—kidney cancer	0.000165	0.000499	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—kidney cancer	0.000159	0.000482	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—kidney cancer	0.000153	0.000464	CcSEcCtD
Agomelatine—Headache—Doxorubicin—kidney cancer	0.000151	0.000457	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—kidney cancer	0.000143	0.000433	CcSEcCtD
Agomelatine—MTNR1A—Signaling Pathways—APC—kidney cancer	4.51e-05	0.000919	CbGpPWpGaD
Agomelatine—HTR2B—G alpha (q) signalling events—PIK3CA—kidney cancer	4.45e-05	0.000907	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	4.33e-05	0.000882	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—MAPK3—kidney cancer	4.32e-05	0.00088	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—MAPK3—kidney cancer	4.32e-05	0.00088	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—POMC—kidney cancer	4.3e-05	0.000875	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—POMC—kidney cancer	4.3e-05	0.000875	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—ANXA1—kidney cancer	4.26e-05	0.000867	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—BRAF—kidney cancer	4.24e-05	0.000864	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—BRAF—kidney cancer	4.24e-05	0.000864	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—MAPK1—kidney cancer	4.11e-05	0.000838	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—MAPK1—kidney cancer	4.11e-05	0.000838	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ACY1—kidney cancer	4.02e-05	0.00082	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	4.02e-05	0.000818	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PDHB—kidney cancer	4e-05	0.000816	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—POMC—kidney cancer	3.99e-05	0.000813	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	3.98e-05	0.000811	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SFRP2—kidney cancer	3.98e-05	0.00081	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP2—kidney cancer	3.97e-05	0.000809	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKAP13—kidney cancer	3.97e-05	0.000809	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—PIK3CA—kidney cancer	3.93e-05	0.0008	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—PIK3CA—kidney cancer	3.93e-05	0.0008	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	3.89e-05	0.000792	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—KRAS—kidney cancer	3.88e-05	0.000791	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—KRAS—kidney cancer	3.88e-05	0.000791	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—ANXA1—kidney cancer	3.87e-05	0.000787	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CCBL1—kidney cancer	3.77e-05	0.000767	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	3.7e-05	0.000754	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—POMC—kidney cancer	3.69e-05	0.000752	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GRB7—kidney cancer	3.63e-05	0.00074	CbGpPWpGaD
Agomelatine—HTR2C—G alpha (q) signalling events—PIK3CA—kidney cancer	3.59e-05	0.000731	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PIK3CA—kidney cancer	3.57e-05	0.000727	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PIK3CA—kidney cancer	3.57e-05	0.000727	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—RAF1—kidney cancer	3.54e-05	0.000721	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—RAF1—kidney cancer	3.54e-05	0.000721	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—RELA—kidney cancer	3.53e-05	0.000718	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—RELA—kidney cancer	3.53e-05	0.000718	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—ERBB2—kidney cancer	3.5e-05	0.000714	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—ERBB2—kidney cancer	3.5e-05	0.000714	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	3.5e-05	0.000712	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MTOR—kidney cancer	3.46e-05	0.000704	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MTOR—kidney cancer	3.46e-05	0.000704	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.43e-05	0.000699	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PDHB—kidney cancer	3.42e-05	0.000697	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—POMC—kidney cancer	3.41e-05	0.000695	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	3.41e-05	0.000694	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ITPR2—kidney cancer	3.38e-05	0.000688	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPAT—kidney cancer	3.26e-05	0.000665	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GLIPR1—kidney cancer	3.26e-05	0.000665	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CDKN1B—kidney cancer	3.24e-05	0.000661	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CDKN1B—kidney cancer	3.24e-05	0.000661	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	3.22e-05	0.000657	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CCBL1—kidney cancer	3.22e-05	0.000655	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	3.21e-05	0.000654	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP2—kidney cancer	3.2e-05	0.000653	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKAP13—kidney cancer	3.2e-05	0.000653	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	3.19e-05	0.00065	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL2—kidney cancer	3.18e-05	0.000647	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL2—kidney cancer	3.18e-05	0.000647	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCND1—kidney cancer	3.1e-05	0.000631	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCND1—kidney cancer	3.1e-05	0.000631	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—JUN—kidney cancer	3.09e-05	0.000629	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—JUN—kidney cancer	3.09e-05	0.000629	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CTNNB1—kidney cancer	3.07e-05	0.000624	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CTNNB1—kidney cancer	3.07e-05	0.000624	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CTNNA1—kidney cancer	3.06e-05	0.000624	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EIF4EBP1—kidney cancer	3.04e-05	0.00062	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HSPB1—kidney cancer	3.04e-05	0.00062	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—FH—kidney cancer	3.04e-05	0.000618	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—APRT—kidney cancer	3.04e-05	0.000618	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTEN—kidney cancer	2.99e-05	0.000609	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTEN—kidney cancer	2.99e-05	0.000609	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.97e-05	0.000604	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GRB7—kidney cancer	2.93e-05	0.000597	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.91e-05	0.000593	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GPC3—kidney cancer	2.85e-05	0.000581	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PSMD7—kidney cancer	2.83e-05	0.000576	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ANXA1—kidney cancer	2.83e-05	0.000576	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TSC1—kidney cancer	2.83e-05	0.000576	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GLIPR1—kidney cancer	2.79e-05	0.000568	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPAT—kidney cancer	2.79e-05	0.000568	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CA2—kidney cancer	2.78e-05	0.000565	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.75e-05	0.000561	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FLT1—kidney cancer	2.74e-05	0.000558	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.73e-05	0.000555	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ITPR2—kidney cancer	2.72e-05	0.000555	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ALAD—kidney cancer	2.71e-05	0.000551	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VEGFA—kidney cancer	2.7e-05	0.00055	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VEGFA—kidney cancer	2.7e-05	0.00055	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ST3GAL2—kidney cancer	2.64e-05	0.000538	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—APRT—kidney cancer	2.59e-05	0.000528	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—FH—kidney cancer	2.59e-05	0.000528	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—POMC—kidney cancer	2.58e-05	0.000526	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ALDH1A1—kidney cancer	2.58e-05	0.000526	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MAPK3—kidney cancer	2.55e-05	0.00052	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MAPK3—kidney cancer	2.55e-05	0.00052	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JUNB—kidney cancer	2.54e-05	0.000518	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PAK1—kidney cancer	2.54e-05	0.000518	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.53e-05	0.000516	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MYC—kidney cancer	2.48e-05	0.000506	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MYC—kidney cancer	2.48e-05	0.000506	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC5A3—kidney cancer	2.47e-05	0.000504	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PGK1—kidney cancer	2.47e-05	0.000504	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CTNNA1—kidney cancer	2.47e-05	0.000503	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EIF4EBP1—kidney cancer	2.46e-05	0.0005	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HSPB1—kidney cancer	2.46e-05	0.0005	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GPC3—kidney cancer	2.44e-05	0.000497	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MAPK1—kidney cancer	2.43e-05	0.000495	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MAPK1—kidney cancer	2.43e-05	0.000495	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—LDHB—kidney cancer	2.43e-05	0.000494	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CA2—kidney cancer	2.37e-05	0.000483	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—POMC—kidney cancer	2.35e-05	0.000478	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALAD—kidney cancer	2.31e-05	0.000471	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KRAS—kidney cancer	2.29e-05	0.000467	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KRAS—kidney cancer	2.29e-05	0.000467	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ANXA1—kidney cancer	2.28e-05	0.000465	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PSMD7—kidney cancer	2.28e-05	0.000465	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TSC1—kidney cancer	2.28e-05	0.000465	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ST3GAL2—kidney cancer	2.26e-05	0.00046	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FLT1—kidney cancer	2.21e-05	0.00045	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALDH1A1—kidney cancer	2.21e-05	0.000449	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PGK1—kidney cancer	2.11e-05	0.000431	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC5A3—kidney cancer	2.11e-05	0.000431	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PIK3CA—kidney cancer	2.11e-05	0.000429	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PIK3CA—kidney cancer	2.11e-05	0.000429	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CA9—kidney cancer	2.1e-05	0.000429	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—POMC—kidney cancer	2.09e-05	0.000425	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IGF2—kidney cancer	2.08e-05	0.000423	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—LDHB—kidney cancer	2.07e-05	0.000422	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN2B—kidney cancer	2.07e-05	0.000421	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.06e-05	0.000419	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PAK1—kidney cancer	2.05e-05	0.000418	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JUNB—kidney cancer	2.05e-05	0.000418	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—kidney cancer	2.04e-05	0.000415	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—kidney cancer	2.04e-05	0.000415	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IGF1R—kidney cancer	2.01e-05	0.000409	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—RAF1—kidney cancer	1.94e-05	0.000394	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—IL2—kidney cancer	1.91e-05	0.000389	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—POMC—kidney cancer	1.89e-05	0.000386	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CA9—kidney cancer	1.8e-05	0.000366	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CRABP1—kidney cancer	1.79e-05	0.000364	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.76e-05	0.000358	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL2—kidney cancer	1.74e-05	0.000353	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF2—kidney cancer	1.68e-05	0.000341	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN2B—kidney cancer	1.67e-05	0.00034	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ITPR2—kidney cancer	1.66e-05	0.000339	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HIF1A—kidney cancer	1.65e-05	0.000337	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TSC2—kidney cancer	1.65e-05	0.000336	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF1R—kidney cancer	1.62e-05	0.00033	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KDR—kidney cancer	1.58e-05	0.000322	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—RAF1—kidney cancer	1.56e-05	0.000318	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—kidney cancer	1.54e-05	0.000314	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.53e-05	0.000312	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CRABP1—kidney cancer	1.53e-05	0.000311	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTT1—kidney cancer	1.52e-05	0.000309	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ACHE—kidney cancer	1.52e-05	0.000309	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KIT—kidney cancer	1.46e-05	0.000297	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—APC—kidney cancer	1.46e-05	0.000297	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SCARB1—kidney cancer	1.44e-05	0.000292	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ITPR2—kidney cancer	1.42e-05	0.000289	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS1—kidney cancer	1.42e-05	0.000289	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—kidney cancer	1.4e-05	0.000285	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK3—kidney cancer	1.4e-05	0.000284	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PSMD7—kidney cancer	1.39e-05	0.000284	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—POMC—kidney cancer	1.39e-05	0.000282	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BRAF—kidney cancer	1.37e-05	0.000279	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HIF1A—kidney cancer	1.33e-05	0.000272	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TSC2—kidney cancer	1.33e-05	0.000271	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK1—kidney cancer	1.33e-05	0.00027	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—BCHE—kidney cancer	1.32e-05	0.000269	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.31e-05	0.000267	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC5A5—kidney cancer	1.3e-05	0.000266	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ACHE—kidney cancer	1.3e-05	0.000264	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTT1—kidney cancer	1.3e-05	0.000264	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KDR—kidney cancer	1.28e-05	0.00026	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—kidney cancer	1.27e-05	0.000258	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC2A1—kidney cancer	1.26e-05	0.000257	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—kidney cancer	1.25e-05	0.000255	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SCARB1—kidney cancer	1.23e-05	0.00025	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.22e-05	0.000249	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS1—kidney cancer	1.21e-05	0.000247	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PSMD7—kidney cancer	1.19e-05	0.000243	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KIT—kidney cancer	1.18e-05	0.000239	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—APC—kidney cancer	1.18e-05	0.000239	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—kidney cancer	1.15e-05	0.000235	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RAF1—kidney cancer	1.14e-05	0.000233	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RELA—kidney cancer	1.14e-05	0.000232	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ERBB2—kidney cancer	1.13e-05	0.00023	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—BCHE—kidney cancer	1.13e-05	0.00023	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	1.13e-05	0.000229	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—POMC—kidney cancer	1.12e-05	0.000228	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MTOR—kidney cancer	1.12e-05	0.000227	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.12e-05	0.000227	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BRAF—kidney cancer	1.1e-05	0.000225	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.08e-05	0.000219	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	1.07e-05	0.000218	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.07e-05	0.000217	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTP1—kidney cancer	1.05e-05	0.000214	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1B—kidney cancer	1.05e-05	0.000213	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.04e-05	0.000213	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—kidney cancer	1.03e-05	0.000209	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	1.02e-05	0.000208	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—kidney cancer	1.01e-05	0.000206	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—kidney cancer	9.99e-06	0.000204	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JUN—kidney cancer	9.97e-06	0.000203	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ABCB1—kidney cancer	9.95e-06	0.000203	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CTNNB1—kidney cancer	9.9e-06	0.000202	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTM1—kidney cancer	9.66e-06	0.000197	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—kidney cancer	9.64e-06	0.000196	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	9.29e-06	0.000189	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RAF1—kidney cancer	9.22e-06	0.000188	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RELA—kidney cancer	9.18e-06	0.000187	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1A1—kidney cancer	9.16e-06	0.000187	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB2—kidney cancer	9.12e-06	0.000186	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.11e-06	0.000186	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MTOR—kidney cancer	9e-06	0.000183	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTP1—kidney cancer	8.98e-06	0.000183	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—kidney cancer	8.71e-06	0.000177	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCB1—kidney cancer	8.5e-06	0.000173	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	8.45e-06	0.000172	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—kidney cancer	8.27e-06	0.000168	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTM1—kidney cancer	8.25e-06	0.000168	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK3—kidney cancer	8.24e-06	0.000168	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—kidney cancer	8.06e-06	0.000164	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JUN—kidney cancer	8.04e-06	0.000164	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—kidney cancer	8.02e-06	0.000163	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	7.98e-06	0.000163	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK1—kidney cancer	7.84e-06	0.00016	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1A1—kidney cancer	7.83e-06	0.000159	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—kidney cancer	7.78e-06	0.000158	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.52e-06	0.000153	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—kidney cancer	7.41e-06	0.000151	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	7.03e-06	0.000143	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—POMC—kidney cancer	6.83e-06	0.000139	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	6.8e-06	0.000139	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	6.65e-06	0.000135	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—kidney cancer	6.58e-06	0.000134	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—kidney cancer	6.47e-06	0.000132	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.43e-06	0.000131	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	6.33e-06	0.000129	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—kidney cancer	5.97e-06	0.000122	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—POMC—kidney cancer	5.83e-06	0.000119	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	5.49e-06	0.000112	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—kidney cancer	5.45e-06	0.000111	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—kidney cancer	5.31e-06	0.000108	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—kidney cancer	4.75e-06	9.67e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—kidney cancer	4.65e-06	9.48e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—kidney cancer	4.06e-06	8.27e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—kidney cancer	3.35e-06	6.82e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.86e-06	5.83e-05	CbGpPWpGaD
